Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sulindac is not an effective primary treatment for familial adenomatous polyposis

Standard doses of sulindac do not prevent the development of adenomas in patients with familial adenomatous polyposis, according to research published in this week's New England Journal of Medicine.

News image

fiogf49gjkf04

Researchers from the Netherlands and the USA investigated whether sulindac, a nonsteroidal antiinflammatory drug (NSAID), acts as a chemopreventive agent in patients with familial adenomatous polyposis.

A total of 41 young individuals (age range, 8 to 25 years) were included in the randomized, double blind, placebo-controlled study.

All patients were genotypically affected with familial adenomatous polyposis but phenotypically unaffected.

The subjects received either 75 or 150 mg of sulindac orally, twice a day, or identical-appearing placebo tablets for 48 months.

The number and size of new adenomas and side effects of therapy were evaluated every 4 months, for 4 years.

In addition, the levels of 5 major prostaglandins were serially measured in biopsy specimens of normal-appearing colorectal mucosa.

After 4 years of treatment, the average rate of compliance exceeded 76% in the sulindac group.

The team found that mucosal prostaglandin levels were lower in this group than in the placebo group.

During the course of the study, adenomas developed in 9 of 21 subjects (43%) in the sulindac group and 11 of 20 subjects in the placebo group (55%).

Prophylactic colectomy remains treatment of choice in familial adenomatous polyposis.
New England Journal of Medicine
There were found to be no significant differences in the mean number or size of polyps between the groups.

Furthermore, sulindac was not found to slow the development of adenomas, according to an evaluation involving linear longitudinal methods.

Dr Francis M. Giardiello, of the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, said on behalf of colleagues, "Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis."

"Our results do not provide support for the use of NSAIDs, such as sulindac, for the primary treatment of familial adenomatous polyposis.

"Prophylactic colectomy remains the treatment of choice to prevent colorectal cancer in patients with this disorder," it was concluded.

In an accompanying Editorial, Ian Chau and David Cunningham, of the Royal Marsden Hospital, Surrey, England, point out that determining the optimal dose, schedule, and duration of this treatment for malignant disease, in the appropriate clinical context, is a major challenge.

"With these imperatives in mind, and despite the relatively disappointing results with respect to their ability to prevent adenomatous polyps in patients in familial adenomatous polyposis, NSAIDs and cyclooxygenase-2 inhibitors may yet be shown to have a role in the primary prevention or treatment of established colorectal cancer," they conclude.

N Engl J Med 2002; 346 (14): 1054-9, 1085-7
05 April 2002

Go to top of page Email this page Email this page to a colleague

 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us